Beyond Air Inc XAIR
News
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
